Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the EBITDA margin high or low?
The EBITDA margin of -408000.00% is 819% below its 3-year average of -44415.48%, near the low end of its 3-year range (-408000.00%–58.93%).
Reported quarterly EBITDA margin; no daily interpolation. Q4 FY2025 (2025-12-31): -115800.00%.
EBITDA MARGIN
-408000.00%
EBITDA MARGIN AVG TTM
N/A
EBITDA MARGIN AVG 3Y
-55534.08%
EBITDA MARGIN AVG 5Y
N/A
EBITDA MARGIN AVG 10Y
N/A
EBITDA MARGIN AVG 15Y
N/A
EBITDA MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
-634.68%
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Genelux Corporation
Market Cap
$116.59M
EBITDA Margin
-408000.00%
TTM Avg
N/A
3Y Avg
-55534.08%
5Y Avg
N/A
Market Cap
$117.43M
EBITDA Margin
-254.86%
TTM Avg
-347.69%
3Y Avg
-398.28%
5Y Avg
-4102.41%
Market Cap
$118.02M
EBITDA Margin
-1187.82%
TTM Avg
-1407.84%
3Y Avg
-970.99%
5Y Avg
-809.42%
Market Cap
$118.50M
EBITDA Margin
-699.90%
TTM Avg
-1930.94%
3Y Avg
-1689.05%
5Y Avg
-1903.35%
Market Cap
$118.63M
EBITDA Margin
-29.32%
TTM Avg
-13.32%
3Y Avg
-6.17%
5Y Avg
-1.07%
Market Cap
$115.55M
EBITDA Margin
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$113.77M
EBITDA Margin
-254.71%
TTM Avg
-369.64%
3Y Avg
-290.17%
5Y Avg
-290.17%
Market Cap
$112.56M
EBITDA Margin
-475.96%
TTM Avg
-475.96%
3Y Avg
-272.89%
5Y Avg
-272.89%
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Genelux Corporation (GNLX) | $116.59M | -408000.00% | N/A | -55534.08% | N/A |
| Foghorn Therapeutics Inc. (FHTX)vs › | $117.43M | -254.86% | -347.69% | -398.28% | -4102.41% |
| Caribou Biosciences, Inc. (CRBU)vs › | $118.02M | -1187.82% | -1407.84% | -970.99% | -809.42% |
| Insight Molecular Diagnostics Inc. (IMDX)vs › | $118.50M | -699.90% | -1930.94% | -1689.05% | -1903.35% |
| BGM Group Ltd. (BGM)vs › | $118.63M | -29.32% | -13.32% | -6.17% | -1.07% |
| Aardvark Therapeutics, Inc. Common Stock (AARD)vs › | $115.55M | N/A | N/A | N/A | N/A |
| TuHURA Biosciences, Inc. (HURA)vs › | $119.09M | N/A | N/A | N/A | N/A |
| Coya Therapeutics, Inc. (COYA)vs › | $113.77M | -254.71% | -369.64% | -290.17% | -290.17% |
| LENZ Therapeutics, Inc. (LENZ)vs › | $112.56M | -475.96% | -475.96% | -272.89% | -272.89% |
| Black Diamond Therapeutics, Inc. (BDTX)vs › | $111.17M | 28.85% | 28.85% | 28.85% | 28.85% |
Gross Margin
-7075.0%
EBITDA Margin
-408000.0%
Operating Margin
-415175.0%
Net Margin
-422412.5%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EBITDA MARGIN |
|---|---|
| 2025-12-31 | -115800.00% |
| 2024-03-31 | -98337.50% |
| 2023-03-31 | -3651.76% |
| 2022-12-31 | -4347.06% |
| 2022-09-30 | 58.93% |
